Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia

Por Shih, Alan H, Meydan, Cem, Shank, Kaitlyn, Garrett-Bakelman, Francine E, Ward, Patrick S, Intlekofer, Andrew, Nazir, Abbas, Stein, Eytan, Knapp, Kristina, Glass, Jacob, Travins, Jeremy, Straley, Kim, Gliser, Camelia, Mason, Chris, Yen, Katharine, Thompson, Craig B, Melnick, Ari, Levine, Ross L
Publicado no Cancer Discov (2017)

Mutant IDH inhibits HNF4α to block hepatocyte differentiation and promote biliary cancer

Por Saha, Supriya K., Parachoniak, Christine A., Ghanta, Krishna S., Fitamant, Julien, Ross, Kenneth N., Najem, Mortada S., Gurumurthy, Sushma, Akbay, Esra A., Sia, Daniela, Cornella, Helena, Miltiadous, Oriana, Walesky, Chad, Deshpande, Vikram, Zhu, Andrew X., Hezel, Aram F., Yen, Katharine, Straley, Kim, Travins, Jeremy, Popovici-Muller, Janeta, Gliser, Camelia, Ferrone, Cristina R., Apte, Udayan, Llovet, Josep M., Wong, Kwok-Kin, Ramaswamy, Sridhar, Bardeesy, Nabeel
Publicado no Nature (2014)